Fig. 2

Adoptive T cell immunotherapy. Tumor mass can be surgically excised, fragmented, and placed in a flask, which contains T cell growth factors, such as interleukin-2 (IL-2). This will induce the proliferation of tumor-infiltrating lymphocytes, in order to expand tumor-specific T cells. Expanded tumor specific T cells will be reinfused into cancer patients in order to induce potent anti-tumor immune responses